Clinical Trial: A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers
Detailed Summary:
Sponsor: Boryung Pharmaceutical Co., Ltd
Current Primary Outcome:
- Maximum observed concentration(Cmax) of Lafutidine and Irsogladine maleate [ Time Frame: 0~36 hour after medication ]
- Area under the plasma drug concentration-time curve(AUClast) of Lafutidine and Irsogladine maleate [ Time Frame: 0~36 hour after medication ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Boryung Pharmaceutical Co., Ltd
Dates:
Date Received: April 21, 2016
Date Started: April 15, 2016
Date Completion:
Last Updated: February 6, 2017
Last Verified: February 2017
